361 related articles for article (PubMed ID: 36052066)
21. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
22. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
23. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.
Warren EH; Deeg HJ
Tissue Antigens; 2013 Apr; 81(4):183-93. PubMed ID: 23510414
[TBL] [Abstract][Full Text] [Related]
24. Chimerism, the Microenvironment and Control of Leukemia.
Deeg HJ
Front Immunol; 2021; 12():652105. PubMed ID: 33968052
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
[TBL] [Abstract][Full Text] [Related]
26. Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion.
Koster EAS; Bonneville EF; Borne PAVD; van Balen P; Marijt EWA; Tjon JML; Snijders TJF; van Lammeren D; Veelken H; Putter H; Falkenburg JHF; Halkes CJM; de Wreede LC
Front Immunol; 2023; 14():1208814. PubMed ID: 37593737
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
28. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
Waller EK; Boyer M
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
[TBL] [Abstract][Full Text] [Related]
29. Accumulation of T-cell-suppressive PD-L1
Baur R; Karl F; Böttcher-Loschinski R; Stoll A; Völkl S; Gießl A; Flamann C; Bruns H; Schlötzer-Schrehardt U; Böttcher M; Schewe DM; Fischer T; Jitschin R; Mackensen A; Mougiakakos D
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898735
[TBL] [Abstract][Full Text] [Related]
30. IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
Lu Y; Giver CR; Sharma A; Li JM; Darlak KA; Owens LM; Roback JD; Galipeau J; Waller EK
Blood; 2012 Jan; 119(4):1075-85. PubMed ID: 22130799
[TBL] [Abstract][Full Text] [Related]
31. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
Front Immunol; 2020; 11():181. PubMed ID: 32117306
[TBL] [Abstract][Full Text] [Related]
33. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation.
Hashimoto D; Chow A; Greter M; Saenger Y; Kwan WH; Leboeuf M; Ginhoux F; Ochando JC; Kunisaki Y; van Rooijen N; Liu C; Teshima T; Heeger PS; Stanley ER; Frenette PS; Merad M
J Exp Med; 2011 May; 208(5):1069-82. PubMed ID: 21536742
[TBL] [Abstract][Full Text] [Related]
34. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
Du W; Cao X
Front Immunol; 2018; 9():2979. PubMed ID: 30631325
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
37. Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation.
Dertschnig S; Passweg J; Bucher C; Medinger M; Tzankov A
Cell Immunol; 2023 Jul; 388-389():104719. PubMed ID: 37141843
[TBL] [Abstract][Full Text] [Related]
38. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
39. How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?
Aizawa K; Peltier D; Matsuki E; Toubai T
Transfus Apher Sci; 2022 Apr; 61(2):103405. PubMed ID: 35210194
[TBL] [Abstract][Full Text] [Related]
40. [Evidence of GVHD/GVL in allogeneic hematopoietic stem cell transplantation from sex-mismatched donors].
Nakasone H
Rinsho Ketsueki; 2024; 65(4):265-271. PubMed ID: 38684437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]